Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Verrica Pharmaceuticals (VRCA) EPS (Basic) (2021 - 2025)

Verrica Pharmaceuticals (VRCA) has 5 years of EPS (Basic) data on record, last reported at -$0.65 in Q4 2025.

  • For Q4 2025, EPS (Basic) rose 95.18% year-over-year to -$0.65; the TTM value through Dec 2025 reached -$1.68, up 93.64%, while the annual FY2025 figure was -$1.68, 88.63% up from the prior year.
  • EPS (Basic) reached -$0.65 in Q4 2025 per VRCA's latest filing, down from -$0.02 in the prior quarter.
  • Across five years, EPS (Basic) topped out at $0.1 in Q3 2022 and bottomed at -$13.48 in Q4 2024.
  • Average EPS (Basic) over 5 years is -$1.58, with a median of -$0.4 recorded in 2021.
  • Peak YoY movement for EPS (Basic): soared 121.28% in 2022, then tumbled 3079.17% in 2024.
  • A 5-year view of EPS (Basic) shows it stood at -$0.35 in 2021, then soared by 60.0% to -$0.14 in 2022, then plummeted by 292.86% to -$0.55 in 2023, then plummeted by 2350.91% to -$13.48 in 2024, then skyrocketed by 95.18% to -$0.65 in 2025.
  • Per Business Quant database, its latest 3 readings for EPS (Basic) were -$0.65 in Q4 2025, -$0.02 in Q3 2025, and -$0.91 in Q2 2025.